Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Falkensee – page 14

1 865 clinical trials in Falkensee, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Falkensee at a glance
1 865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 865 trials in Falkensee

Open in trial search

Obesity

Recruiting

Phase 2b Randomized Study of Semaglutide Subcutaneous Depot for Weight Reduction in Adults with Obesity or Overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Camurus AB

Asthma

Recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.

Asthma

Recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC

A study of SAR448851 with florquinitau (18F) to assess safety and effectiveness in early Alzheimer’s disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Amgen Inc.

Asthma

Recruiting

Study of Three Doses of Frevecitinib (KN-002) in Adults with Severe Asthma Not Controlled by Medium‑to‑High Dose Inhaled Steroid/LABA Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Frevecitinib
  • Sponsor:Kinaset Therapeutics Inc.

Breast cancer+1

Recruiting

Evaluation of zongertinib, fulvestrant and goserelin acetate in patients with HR‑positive HER2‑negative advanced breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Falkensee

What the registry says about research in the country

01 Metabolic Disorders

Innovative research focusing on Type 2 Diabetes Mellitus management and glycemic control, evaluating new therapeutic approaches including novel compounds and established treatments.

  • Glycemic Control Studies
  • Cardiovascular Outcomes
  • Diabetes Management

Multiple trials are investigating both single and combination therapies for improving patient outcomes.

02 Cardiovascular Health

Comprehensive studies addressing atherosclerotic cardiovascular disease and cholesterol management, examining innovative treatments for reducing major adverse cardiovascular events.

  • Lipid Management
  • Cardiovascular Risk Reduction
  • Arterial Health

Research focuses on comparing effectiveness of different therapeutic approaches for cholesterol control.

03 Metabolic and Renal Health

Groundbreaking research combining treatments for chronic kidney disease and metabolic conditions, including studies on weight management and obesity-related complications.

  • Weight Management
  • Kidney Disease Progression
  • Blood Pressure Control

Trials evaluate combination therapies targeting multiple health conditions simultaneously.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.